Synonyms: Compound A [WO2022237720] | JNJ-75276617 | JNJ75276617
Compound class:
Synthetic organic
Comment: The structure for bleximenib was obtained from proposed INN list 129 (August 2023). This maps to a PubChem CID that describes it as a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor. The compound is claimed in patent WO2022237720A1 (Janssen, Johnson & Johnson), for potential to treat hematological malignancies (in combination with a BCL-2 inhibitor) [1]. This class of agents disrupts the interaction between MLL oncoproteins (re-arranged MLL fusion proteins that are found in aggressive human acute leukemias) and the tumour suppressor protein menin (MEN1, O00255). Menin is an essential oncogenic co-factor for the leukemogenicity of MLL fusion proteins. The INN was subsequently mapped to the company code JNJ-75276617 [2].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
N-ethyl-5-fluoro-2-[[5-[2-[(3R)-6-[2-methoxyethyl(methyl)amino]-2-methylhexan-3-yl]-2,7-diazaspiro[3.4]octan-7-yl]-1,2,4-triazin-6-yl]oxy]-N-propan-2-ylbenzamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
12759 | bleximenib |
Synonyms ![]() |
Compound A [WO2022237720] | JNJ-75276617 | JNJ75276617 |
Database Links ![]() |
|
CAS Registry No. | 2654081-35-1 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL5314509 |
GtoPdb PubChem SID | 485205987 |
PubChem CID | 156498110 |
Search Google for chemical match using the InChIKey | PDUGAXSIWNMIBQ-HHHXNRCGSA-N |
Search Google for chemicals with the same backbone | PDUGAXSIWNMIBQ |
Search PubMed clinical trials | bleximenib |
Search PubMed titles | bleximenib |
Search PubMed titles/abstracts | bleximenib |
UniChem Compound Search for chemical match using the InChIKey | PDUGAXSIWNMIBQ-HHHXNRCGSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | PDUGAXSIWNMIBQ-HHHXNRCGSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Bleximenib (links to external site)
Cat. No. HY-148669 |